Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T03:38:10.343Z Has data issue: false hasContentIssue false
  • English
  • Français

Cannabis use and genetic predisposition for schizophrenia: a case-control study

Published online by Cambridge University Press:  19 May 2008

W. Veling ,
J. P. Mackenbach ,
J. van Os  and
H. W. Hoek
W. Veling*
Affiliation:
Parnassia Psychiatric Institute, The Hague, The Netherlands Erasmus Medical Center, Department of Public Health, Rotterdam, The Netherlands
J. P. Mackenbach
Affiliation:
Erasmus Medical Center, Department of Public Health, Rotterdam, The Netherlands
J. van Os
Affiliation:
European Graduate School of Neuroscience and South Limburg Mental Health Research and Teaching Network, Maastricht University, Maastricht, The Netherlands Division of Psychological Medicine, Institute of Psychiatry, London, UK
H. W. Hoek
Affiliation:
Parnassia Psychiatric Institute, The Hague, The Netherlands Columbia University, Department of Epidemiology, New York, NY, USA University Medical Center Groningen, Department of Psychiatry, Groningen, The Netherlands
*
*Address for correspondence: W. Veling, M.D., Ph.D., Parnassia Psychiatric Institute, Department of Research, Mangostraat 15, 2552 KS The Hague, The Netherlands. (Email: w.veling@parnassia.nl)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Cannabis use may be a risk factor for schizophrenia. Part of this association may be explained by genotype–environment interaction, and part of it by genotype–environment correlation. The latter issue has not been explored. We investigated whether cannabis use is associated with schizophrenia, and whether gene–environment correlation contributes to this association, by examining the prevalence of cannabis use in groups with different levels of genetic predisposition for schizophrenia.

Method

Case-control study of first-episode schizophrenia. Cases included all non-Western immigrants who made first contact with a physician for schizophrenia in The Hague, The Netherlands, between October 2000 and July 2005 (n=100; highest genetic predisposition). Two matched control groups were recruited, one among siblings of the cases (n=63; intermediate genetic predisposition) and one among immigrants who made contact with non-psychiatric secondary health-care services (n=100; lowest genetic predisposition). Conditional logistic regression analyses were used to predict schizophrenia as a function of cannabis use, and cannabis use as a function of genetic predisposition for schizophrenia.

Results

Cases had used cannabis significantly more often than their siblings and general hospital controls (59, 21 and 21% respectively). Cannabis use predicted schizophrenia [adjusted odds ratio (OR) cases compared to general hospital controls 7.8, 95% confidence interval (CI) 2.7–22.6; adjusted OR cases compared to siblings 15.9 (95% CI 1.5–167.1)], but genetic predisposition for schizophrenia did not predict cannabis use [adjusted OR intermediate predisposition compared to lowest predisposition 1.2 (95% CI 0.4–3.8)].

Conclusions

Cannabis use was associated with schizophrenia but there was no evidence for genotype–environment correlation.

Keywords

Cannabisgene–environmental correlationschizophrenia
Type
Original Articles
Information
Psychological Medicine , Volume 38 , Issue 9 , September 2008 , pp. 1251 - 1256
Copyright
Copyright © 2008 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, NC, Flaum, M, Arndt, S (1992). The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry 49, 615–623.CrossRefGoogle ScholarPubMed
Arseneault, L, Cannon, M, Witton, J, Murray, RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110–117.CrossRefGoogle ScholarPubMed
Caspi, A, Moffitt, TE, Cannon, M, McClay, J, Murray, R, Harrington, H, Taylor, A, Arseneault, L, Williams, B, Braithwaite, A, Poulton, R, Craig, IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biological Psychiatry 57, 1117–1127.CrossRefGoogle Scholar
Collip, D, Myin-Germeys, I, Van Os, J (2008). Does the concept of ‘sensitization’ provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophrenia Bulletin 34, 220–225.CrossRefGoogle ScholarPubMed
Eaves, L, Chen, S, Neale, M, Maes, HH, Silberg, J (2005). Questions, models, and methods in psychiatric genetetics. In Psychiatric Genetics (ed. Kendler, K. S. and Eaves, L.), pp. 19–94. American Psychiatric Publishing: Washington, DC.Google Scholar
Ferdinand, RF, Sondeijker, F, Van der Ende, J, Selten, JP, Huizink, A, Verhulst, FC (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100, 612–618.CrossRefGoogle ScholarPubMed
Henquet, C, Krabbendam, L, Spauwen, J, Kaplan, C, Lieb, R, Wittchen, HU, van Os, J (2005 a). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11–14.CrossRefGoogle ScholarPubMed
Henquet, C, Murray, R, Linszen, D, Van Os, J (2005 b). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608–612.CrossRefGoogle ScholarPubMed
Henquet, C, Rosa, A, Krabbendam, L, Papiol, S, Fananas, L, Drukker, M, Ramaekers, JG, van Os, J (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748–2757.CrossRefGoogle ScholarPubMed
MacLeod, J (2007). Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al. Psychological Medicine 37, 913–916.CrossRefGoogle ScholarPubMed
Moore, THM, Zammit, S, Lingford-Hughes, A, Barnes, TRE, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.CrossRefGoogle ScholarPubMed
Murray, RM, Jones, PB, Susser, E, Van Os, J, Cannon, M (eds) (2003). The Epidemiology of Schizophrenia. Cambridge University Press: Cambridge.Google Scholar
Smitten, MH, Smeets, RMW, Van den Brink, W (1998). Composite International Diagnostic Interview (CIDI), Version 2.1. World Health Organization: Amsterdam.Google Scholar
Stefanis, NC, Delespaul, P, Henquet, C, Bakoula, C, Stefanis, CN, van Os, J (2004). Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99, 1333–1341.CrossRefGoogle ScholarPubMed
Veling, W, Selten, JP, Veen, N, Laan, W, Blom, JD, Hoek, HW (2006). Incidence of schizophrenia among ethnic minorities in the Netherlands: a four-year first-contact study. Schizophrenia Research 86, 189–193.CrossRefGoogle ScholarPubMed
Verdoux, H, Gindre, C, Sorbara, F, Tournier, M, Swendsen, JD (2003). Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine 33, 23–32.CrossRefGoogle ScholarPubMed